Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
PAHC vs ZTS
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
PAHC vs ZTS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2.38B | $46.95B |
| Revenue (TTM) | $1.46B | $9.47B |
| Net Income (TTM) | $92M | $2.67B |
| Gross Margin | 31.9% | 70.5% |
| Operating Margin | 11.6% | 38.0% |
| Forward P/E | 19.3x | 15.8x |
| Total Debt | $762M | $9.49B |
| Cash & Equiv. | $68M | $2.31B |
PAHC vs ZTS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Phibro Animal Healt… (PAHC) | 100 | 223.8 | +123.8% |
| Zoetis Inc. (ZTS) | 100 | 79.8 | -20.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PAHC vs ZTS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PAHC is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
- 207.3% 10Y total return vs ZTS's 158.5%
- 27.4% revenue growth vs ZTS's 2.3%
ZTS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 13 yrs, beta 0.90, yield 1.8%
- Lower volatility, beta 0.90, current ratio 3.03x
- PEG 1.32 vs PAHC's 2.59
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.4% revenue growth vs ZTS's 2.3% | |
| Value | Lower P/E (15.8x vs 19.3x), PEG 1.32 vs 2.59 | |
| Quality / Margins | 28.2% margin vs PAHC's 6.3% | |
| Stability / Safety | Beta 0.90 vs PAHC's 1.38 | |
| Dividends | 1.8% yield, 13-year raise streak, vs PAHC's 0.8% | |
| Momentum (1Y) | +210.5% vs ZTS's -24.4% | |
| Efficiency (ROA) | 18.1% ROA vs PAHC's 6.7%, ROIC 26.9% vs 9.8% |
PAHC vs ZTS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PAHC vs ZTS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ZTS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ZTS is the larger business by revenue, generating $9.5B annually — 6.5x PAHC's $1.5B. ZTS is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to PAHC's 6.3%. On growth, PAHC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $9.5B |
| EBITDAEarnings before interest/tax | $220M | $4.1B |
| Net IncomeAfter-tax profit | $92M | $2.7B |
| Free Cash FlowCash after capex | $47M | $2.3B |
| Gross MarginGross profit ÷ Revenue | +31.9% | +70.5% |
| Operating MarginEBIT ÷ Revenue | +11.6% | +38.0% |
| Net MarginNet income ÷ Revenue | +6.3% | +28.2% |
| FCF MarginFCF ÷ Revenue | +3.2% | +24.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.9% | +3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.4% | +6.2% |
Valuation Metrics
ZTS leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 18.5x trailing earnings, ZTS trades at a 63% valuation discount to PAHC's 49.3x P/E. Adjusting for growth (PEG ratio), ZTS offers better value at 1.54x vs PAHC's 6.60x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.4B | $46.9B |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $54.1B |
| Trailing P/EPrice ÷ TTM EPS | 49.28x | 18.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.33x | 15.83x |
| PEG RatioP/E ÷ EPS growth rate | 6.60x | 1.54x |
| EV / EBITDAEnterprise value multiple | 19.67x | 13.25x |
| Price / SalesMarket cap ÷ Revenue | 1.83x | 4.96x |
| Price / BookPrice ÷ Book value/share | 8.35x | 14.82x |
| Price / FCFMarket cap ÷ FCF | 56.82x | 20.56x |
Profitability & Efficiency
ZTS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ZTS delivers a 58.2% return on equity — every $100 of shareholder capital generates $58 in annual profit, vs $31 for PAHC. PAHC carries lower financial leverage with a 2.67x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZTS's 2.85x. On the Piotroski fundamental quality scale (0–9), ZTS scores 7/9 vs PAHC's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +30.8% | +58.2% |
| ROA (TTM)Return on assets | +6.7% | +18.1% |
| ROICReturn on invested capital | +9.8% | +26.9% |
| ROCEReturn on capital employed | +12.0% | +29.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 2.67x | 2.85x |
| Net DebtTotal debt minus cash | $694M | $7.2B |
| Cash & Equiv.Liquid assets | $68M | $2.3B |
| Total DebtShort + long-term debt | $762M | $9.5B |
| Interest CoverageEBIT ÷ Interest expense | 3.64x | 15.13x |
Total Returns (Dividends Reinvested)
PAHC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PAHC five years ago would be worth $23,641 today (with dividends reinvested), compared to $7,122 for ZTS. Over the past 12 months, PAHC leads with a +210.5% total return vs ZTS's -24.4%. The 3-year compound annual growth rate (CAGR) favors PAHC at 61.1% vs ZTS's -14.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +57.5% | -10.8% |
| 1-Year ReturnPast 12 months | +210.5% | -24.4% |
| 3-Year ReturnCumulative with dividends | +318.1% | -36.8% |
| 5-Year ReturnCumulative with dividends | +136.4% | -28.8% |
| 10-Year ReturnCumulative with dividends | +207.3% | +158.5% |
| CAGR (3Y)Annualised 3-year return | +61.1% | -14.2% |
Risk & Volatility
Evenly matched — PAHC and ZTS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ZTS is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than PAHC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PAHC currently trades 97.6% from its 52-week high vs ZTS's 64.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 0.90x |
| 52-Week HighHighest price in past year | $60.08 | $172.23 |
| 52-Week LowLowest price in past year | $18.89 | $110.94 |
| % of 52W HighCurrent price vs 52-week peak | +97.6% | +64.6% |
| RSI (14)Momentum oscillator 0–100 | 54.5 | 37.4 |
| Avg Volume (50D)Average daily shares traded | 273K | 3.2M |
Analyst Outlook
ZTS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates PAHC as "Buy" and ZTS as "Hold". Consensus price targets imply 28.6% upside for ZTS (target: $143) vs -16.4% for PAHC (target: $49). For income investors, ZTS offers the higher dividend yield at 1.80% vs PAHC's 0.81%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $49.00 | $143.00 |
| # AnalystsCovering analysts | 13 | 30 |
| Dividend YieldAnnual dividend ÷ price | +0.8% | +1.8% |
| Dividend StreakConsecutive years of raises | 0 | 13 |
| Dividend / ShareAnnual DPS | $0.48 | $2.00 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.9% |
ZTS leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PAHC leads in 1 (Total Returns). 1 tied.
PAHC vs ZTS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PAHC or ZTS a better buy right now?
For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.
4% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 18. 5x trailing P/E (15. 8x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PAHC or ZTS?
On trailing P/E, Zoetis Inc.
(ZTS) is the cheapest at 18. 5x versus Phibro Animal Health Corporation at 49. 3x. On forward P/E, Zoetis Inc. is actually cheaper at 15. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 32x versus Phibro Animal Health Corporation's 2. 59x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — PAHC or ZTS?
Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.
4%, compared to -28. 8% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: PAHC returned +207. 3% versus ZTS's +158. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PAHC or ZTS?
By beta (market sensitivity over 5 years), Zoetis Inc.
(ZTS) is the lower-risk stock at 0. 90β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 52% more volatile than ZTS relative to the S&P 500. On balance sheet safety, Phibro Animal Health Corporation (PAHC) carries a lower debt/equity ratio of 3% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PAHC or ZTS?
By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.
4% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 10. 1% for Zoetis Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PAHC or ZTS?
Zoetis Inc.
(ZTS) is the more profitable company, earning 28. 2% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PAHC or ZTS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 32x versus Phibro Animal Health Corporation's 2. 59x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 15. 8x forward P/E versus 19. 3x for Phibro Animal Health Corporation — 3. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 28. 6% to $143. 00.
08Which pays a better dividend — PAHC or ZTS?
All stocks in this comparison pay dividends.
Zoetis Inc. (ZTS) offers the highest yield at 1. 8%, versus 0. 8% for Phibro Animal Health Corporation (PAHC).
09Is PAHC or ZTS better for a retirement portfolio?
For long-horizon retirement investors, Zoetis Inc.
(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 1. 8% yield, +158. 5% 10Y return). Both have compounded well over 10 years (ZTS: +158. 5%, PAHC: +207. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PAHC and ZTS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PAHC is a small-cap high-growth stock; ZTS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.